Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lymphoma, B-Cell × zanubrutinib × Clear all

Phase

Phase 3 2 Phase 2 2 Phase NA 1 Phase 4 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 4 Leukemia, Lymphocytic, Chronic, B-Cell 3 Recurrence 2 Lymphoma, Mantle-Cell 2 Lymphoma, Follicular 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma 2 Leukemia 2 Mature B-Cell Malignancies 1 Lymphoma, B-Cell 1 B-cell Malignancies 1

Interventions

Cyclophosphamide 36 fludarabine 28 Rituximab 25 obinutuzumab 10 fludarabine phosphate 9 Bendamustine Hydrochloride 9 pembrolizumab 7 Vincristine 6 Specimen Handling 6 Prednisone 6 Magnetic Resonance Spectroscopy 6 Leukapheresis 6 Lenalidomide 6 Etoposide 6 venetoclax 5 ibrutinib 5 Inotuzumab Ozogamicin 5 Doxorubicin 5 Biopsy 5 ublituximab 4 tazemetostat 4 glofitamab 4 Interleukin-2 4 polatuzumab vedotin 3 Radiation 3 Nivolumab 3 Ipilimumab 3 Immunotherapy, Adoptive 3 Gemcitabine 3 Dexamethasone 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06824701 2025-12-03

TARZAN

University of Utah

Phase 1 Recruiting

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡